News MSD, AZ partner LaNova bought by Sino Biopharm for $951m LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.
News MSD joins PD-1/VEGF push in cancer with LaNova deal There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.
News AstraZeneca builds in cancer ADCs again, with LaNova deal AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base
News ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
